Asenapine

Nature Reviews Drug Discovery

Volumn 8, Issue 11, 2009, Pages 843-844

  Meltzer, Herbert Y ^a   Dritselis, Argyris ^b   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IQVIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGRANULOCYTOSIS; ANTIPSYCHOTIC ACTIVITY; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; INSULIN RESISTANCE; MANIA; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG APPROVAL; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70350780575     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3027     Document Type: Article

References (20)

1. van Os, J. & Kapur, S. Schizophrenia. Lancet 374, 635-645 (2009).
2. Belmaker, R. H. Bipolar disorder. N. Engl. J. Med. 351, 476-486 (2004).
3. Miyamoto, S. et al. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79-104 (2005).
4. Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 25, 238-246 (1989).
5. Broekkamp, C. L. et al. Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz [2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneimittelforschung 40, 544-549 (1990).
6. De Boer, T. et al. Neurochemical studies with the potential antipsychotic compound trans-5-chloro-2-methyl-2, 3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7] oxepino[4,5-c]pyrrolidine maleate. Arzneimittelforschung 40, 550-554 (1990).
7. Franberg, O. et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 196, 417-429 (2008).
8. Food and Drug Administration. FDA labelling information. FDA website [online] (2009).
9. Shahid, M. et al. Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 23 65-73 (2009).
10. Potkin, S. G., Cohen, M. & Panagides, J. Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial. J. Clin. Psychiatry 68,1492-1500 (2007).
11. Meltzer, H. Y. Treatment-resistant schizophrenia - the role of clozapine. Curr. Med. Res. Opin. 14, 1-20 (1997).
12. Meltzer, H. Y. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60, 82-91 (2003)
13. Tiihonen, J. et al. Mortality in schizophrenia: An 11-year follow-up study of the total Finnish population (FIN11 Study). Lancet 374, 620-627 (2009).
14. Leucht, S. et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 14, 429-447 (2009).
15. Volpi, S. et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry 70, 801-809 (2009).
16. Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 1209-1223 (2005).
17. Tiihonen, J. et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333, 224-227 (2006).
18. IMS MIDAS (IMS Health, 2009).
19. Arnold, C. et al. Credit Suisse Equity Research Report (Credit Suisse Security, 3 Feb 2009).
20. Schott, C. et al. JP Morgan North America Equity Research Report (JP Morgan & Chase, 3 Feb 2009).